论文部分内容阅读
目的:研究雷尼替丁对重症肝病患者肠道及腹腔感染发生的关系。方法:52例重症肝炎及肝硬化患者应用雷尼替丁以防止消化道出血,观察用药后肠道及腹腔感染情况,并以同类患者40例作为对照。结果:雷尼替丁组和对照组的肠道、腹腔感染例数分别为29例和12例,两组对比差异明显(P<0.05)。结论:雷尼替丁可干扰肠道正常菌群,容易导致重症肝病患者肠道及腹腔感染。
Objective: To study the relationship between ranitidine and intestinal and abdominal infections in patients with severe liver disease. Methods: In the 52 patients with severe hepatitis and cirrhosis, ranitidine was used to prevent gastrointestinal bleeding. Intestinal and abdominal infections were observed and 40 cases of similar patients were used as control. Results: The numbers of intestinal and abdominal infections in ranitidine group and control group were 29 cases and 12 cases, respectively. There was significant difference between the two groups (P <0.05). Conclusion: Ranitidine can interfere with the normal intestinal flora, easily lead to intestinal and abdominal infections in patients with severe liver disease.